Tootearendus
Arendatavad Ravimid
Meie uurimis- ja arendusmeeskondade eesmärk on leida ajuhaiguste algpõhjused. Tegutseme kõik ühe eesmärgi nimel: pakkuda uudseid ravimeid, mis parandavad ravistandardit ja on suunatud just neile ajuhaiguste ilmingutele, mille korral on vajadus kõige suurem.
| Project | Area | Phase 1 | Phase 2 | Phase 3 | Filing | ||||
|---|---|---|---|---|---|---|---|---|---|
| Eptinezumab (anti-CGRP mAb)¹ | Migraine prevention² | Filing | |||||||
|
Mode of Action Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. |
|||||||||
| Eptinezumab (anti-CGRP mAb)¹ | Cluster headache | 3 | |||||||
|
Mode of Action Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. *Three phase III clinical trials, supporting registration in Asia, including China and Japan: SUNLIGHT, SUNRISE, and SUNSET trials. |
|||||||||
| Lu AG09222 (anti-PACAP mAb)³ | Migraine prevention² | 2 | |||||||
|
Mode of Action Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology. |
|||||||||
| Lu AG13909 (anti-ACTH mAb)⁴ | Neurohormonal dysfunctions | 1 | |||||||
| Project | Area | Phase 1 | Phase 2 | Phase 3 | Filing | ||||
|---|---|---|---|---|---|---|---|---|---|
| Brexpiprazole⁵ | PTSD⁶ | Filing | |||||||
|
Mode of Action Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. |
|||||||||
| Lu AF28996 (D1-D2 agonist)⁷ | Parkinson's disease | 1 | |||||||
|
Mode of Action Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients. |
|||||||||
| MAGLi program⁸ | Neurology | 1 | |||||||
| Bexicaserin (5HT2C agonist) | Developmental and epileptic encephalopathies | 3 | |||||||
| Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Amlenetug (anti α-synuclein mAb) | Synucleinopathies (MSA) | 3 |
| Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Lu AG22515 (CD40L blocker)⁹ | Neurology | 1 |
Lähemalt lundbeckist
Teadus -ja Arendustöö
Meie tegevuse keskmes on uute ja paremate ravimite uurimine ning arendamine.
Meditsiiniharidus
Tõenduspõhine meditsiiniharidus ja -koolitus tervishoiutöötajatele.
Ülevaade Ajuhaigustest
Ajutervise taastamiseks tuleb kõigepealt olla hästi kursis haiguste endiga.